Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company Drug

AnHeart Therapeutics and Innovent Biologics File Taletrectinib for Marketing Approval in China

Fineline Cube Nov 22, 2023

China’s Center for Drug Evaluation (CDE) has indicated on its website that taletrectinib, an ROS1/NTRK...

Company Deals

Genentech and NVIDIA Collaborate to Advance Drug Discovery with AI

Fineline Cube Nov 22, 2023

Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has entered into a collaboration...

Company Deals

MSD to Acquire Caraway Therapeutics for USD 610 Million to Boost Neurodegenerative Disease Portfolio

Fineline Cube Nov 22, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an agreement to purchase Caraway Therapeutics,...

Company Drug

Janssen Submits Indication Extension Application to FDA for Rybrevant in NSCLC Treatment

Fineline Cube Nov 22, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has filed an indication extension...

Company Deals

EC Healthcare Partners with Jiangxi Rimag Group to Expand Medical Imaging Services

Fineline Cube Nov 22, 2023

China-based EC Healthcare (HKG: 2138) has entered into a partnership with Jiangxi Rimag Group Co.,...

Company Deals

Dizal Pharmaceutical and Wuxi Gaofa Investment to Establish Joint Venture for Auto-Immune Disease Treatments

Fineline Cube Nov 22, 2023

China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into...

Company Deals

BeiGene Ltd Strikes Exclusive Global License Deal with Ensem Therapeutics for CDK2 Inhibitor

Fineline Cube Nov 22, 2023

China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a licensing...

Company Drug

Fosun Pharmaceutical’s FCN-437c filing Accepted for Review by China’s NMPA

Fineline Cube Nov 22, 2023

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National...

Company Deals

XtalPi Inc. and Singapore’s EDDC Broaden Collaboration in AI-Driven Drug Discovery

Fineline Cube Nov 22, 2023

Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a memorandum of...

Company

Merck KGaA Completes Second Phase of Biologics Testing Center Expansion in China

Fineline Cube Nov 22, 2023

Germany’s major life science company, Merck KGaA (ETR: MRK), has announced the completion of the...

Company

Belgium Bans Ozempic for Weight Loss as Global Shortage Persists

Fineline Cube Nov 21, 2023

Belgium has issued a royal decree prohibiting the use of Novo Nordisk’s (NYSE: NVO) diabetes...

Company Deals

Asia Regenerative Medicine Secures Pre-Series A Financing for Bioartificial Organ Development

Fineline Cube Nov 21, 2023

Shenzhen-based bioartificial organ developer, Asia Regenerative Medicine, has reportedly raised tens of millions of renminbi...

Company Drug

CSPC Pharmaceutical’s Glumetinib Earns Breakthrough Therapy Designation in China

Fineline Cube Nov 21, 2023

Glumetinib, a MET targeted tyrosine kinase inhibitor (TKI) co-developed by CSPC Pharmaceutical Group Ltd (HKG:...

Company Medical Device

AstraZeneca Launches Evinova to Enhance Global Clinical Development with Digital Health Solutions

Fineline Cube Nov 21, 2023

UK-based AstraZeneca (AZ; NASDAQ: AZN) has launched Evinova, a digital health solutions provider, with the...

Company Drug

BMS and 2seventy Bio’s Abecma Faces FDA Review Extension

Fineline Cube Nov 21, 2023

The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...

Company Deals

Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project

Fineline Cube Nov 21, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company

Shanghai Pharmaceuticals’ Chairman Zhou Jun Resigns Amid Investigation

Fineline Cube Nov 21, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading Chinese pharmaceutical distribution company, has announced...

Company Deals

VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round

Fineline Cube Nov 21, 2023

China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of...

Company Drug

Jiangsu Aidea Pharmaceutical’s AINUOVIRINE Receives Priority Review Status from CDE

Fineline Cube Nov 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a Chinese pharmaceutical company, has announced that its...

Company Drug

Medilink Therapeutics’ YL201 Earns Orphan Drug Designation for Esophageal Cancer

Fineline Cube Nov 21, 2023

Suzhou-based Medilink Therapeutics has announced that it has obtained orphan drug designation (ODD) from the...

Posts pagination

1 … 422 423 424 … 648

Recent updates

  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.